TRCT
STRO icon

Tower Research Capital (TRC)’s Sutro Biopharma STRO Stock Holding History

Tower Research Capital (TRC)’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,402
Closed -$20.9K – 5584
2025
Q3 		$20.9K Sell
2,402
-86
-3% -$732 ﹤0.01% 3273
2025
Q2 		$17.8K Buy
2,488
+1,117
+81% +$9.13K ﹤0.01% 3744
2025
Q1 		$8.92K Buy
1,371
+600
+78% +$9.45K ﹤0.01% 3841
2024
Q4 		$14.2K Buy
771
+403
+110% +$12.3K ﹤0.01% 3472
2024
Q3 		$12.7K Sell
368
-820
-69% -$32.1K ﹤0.01% 3565
2024
Q2 		$34.8K Buy
1,188
+726
+157% +$28.7K ﹤0.01% 3373
2024
Q1 		$26.1K Sell
462
-478
-51% -$21.1K ﹤0.01% 2767
2023
Q4 		$40.3K Sell
940
-573
-38% -$18.2K ﹤0.01% 3272
2023
Q3 		$52.5K Buy
1,513
+1,171
+342% +$51K ﹤0.01% 2509
2023
Q2 		$15.9K Buy
342
+25
+8% +$1.24K ﹤0.01% 3600
2023
Q1 		$15K Buy
317
+183
+137% +$11.6K ﹤0.01% 3815
2022
Q4 		$11K Sell
134
-191
-59% -$13.3K ﹤0.01% 3869
2022
Q3 		$18K Sell
325
-245
-43% -$14.5K ﹤0.01% 4024
2022
Q2 		$30K Buy
570
+447
+363% +$25K ﹤0.01% 3386
2022
Q1 		$10K Sell
123
-421
-77% -$40.1K ﹤0.01% 4348
2021
Q4 		$81K Buy
544
+242
+80% +$43.4K ﹤0.01% 2377
2021
Q3 		$57K Sell
302
-42
-12% -$7.99K ﹤0.01% 2847
2021
Q2 		$64K Sell
344
-12
-3% -$2.35K ﹤0.01% 2813
2021
Q1 		$81K Buy
356
+147
+70% +$34.9K ﹤0.01% 2752
2020
Q4 		$45K Sell
209
-1,633
-89% -$270K ﹤0.01% 3219
2020
Q3 		$185K Buy
1,842
+1,154
+168% +$109K ﹤0.01% 2649
2020
Q2 		$53K Buy
+688
New +$66K ﹤0.01% 3001
2019
Q4 		– Sell
-11
Closed -$1K – 4318
2019
Q3 		$1K Sell
11
-109
-91% -$11K ﹤0.01% 3922
2019
Q2 		$14K Buy
120
+97
+422% +$10.7K ﹤0.01% 2380
2019
Q1 		$3K Sell
23
-529
-96% -$55K ﹤0.01% 3321
2018
Q4 		$49K Buy
+552
New +$66.6K ﹤0.01% 1299

Other funds holding STRO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Tower Research Capital (TRC)'s STRO Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 2,402 shares — an estimated $20.9K sold.

Tower Research Capital (TRC) first reported a position in STRO in Q4 2018 and held it in 26 quarters. The position peaked at $185K in Q3 2020. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,402 Sutro Biopharma shares in Q4 2025, an estimated $20.9K.
  • Tower Research Capital (TRC) first reported a position in Sutro Biopharma in Q4 2018 and held it in 26 quarters.
  • Tower Research Capital (TRC)'s Sutro Biopharma position peaked at $185K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.